JANILSON SILVA SANTOS
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
Resumo IPEN-doc 09320 Radioiodination of protein using prosthetic group: a convenient way to produce labelled proteins with in vivo stability2002 - SANTOS, J.S.; COLTURATO, M.T.; MURAMOTO, E.; SILVA, C.P.G.; ARAUJO, E.B.Artigo IPEN-doc 07224 Obtenção de um grupamento prostético para marcação de proteínas com radioiodo2000 - SANTOS, J.S.; COLTURATO, M.T.; ARAUJO, E.B.O uso de anticorpos e peptídeos radiomarcados em radioimunodetecção e radioimunoterapia, tem sido extensivamente estudado nas últimas décadas. O principal problema associado ao uso de proteínas radioiodadas é a deiodação observada “in vivo”. Diversas metodologias de marcação indireta de proteínas, têm sido estudadas a fim de minimizar esta dehalogenação. O objetivo deste trabalho foi a obtenção do grupamento prostético iodado N-succinimidil 4-radioiodo benzoato (SIB), a partir iodação do ácido p-bromo-benzóico e posterior reação com TSTU. Os resultados mostram que a obtenção deste grupamento prostético apresenta um bom rendimento.Resumo IPEN-doc 13838 Comparative pharmacokinetic and biodistribution studies of two novel [sup(177)Lu]bombesin analogues for prostate cancer target therapy2008 - PUJATTI, P.B.; SANTOS, J.S.; MENGATTI, J.; ARAUJO, E.B.Artigo IPEN-doc 09583 Radioiodination of proteins using prosthetic group: a convenient way to produce labelled proteins with in vivo stability2002 - SANTOS, J.S.; MURAMOTO, E.; COLTURATO, M.T.; SILVA, C.P.G.; ARAUJO, E.B.Artigo IPEN-doc 09740 Optimization of a convenient route to produce N-succinimidyl 4-radiodobenzoate for radioiodination of proteins2003 - ARAUJO, E.B.; SANTOS, J.S.; COLTURATO, M.T.; MURAMOTO, E.; SILVA, C.P.G.Artigo IPEN-doc 16664 Development of a new bombesin analog radiolabelled with lutetium-1772010 - PUJATTI, P.B.; SANTOS, J.S.; MASSICANO, A.V.F.; MENGATTI, J.; ARAUJO, E.B. deIn this work we describe the first results of radiolabeling with lutetium-177 (177Lu) and in vivo biodistribution and pharmacokinetics studies in normal Balb-c mice of a new bombesin analog (BEFG2) – DOTA-Phe-X-BBN(6-14), where X is a spacer of two aminoacids. Bombesin (BBN) is an amphibian analog of human gastrin releasing peptide (GRP). Development of radiolabeled BBN derivatives as agents for diagnostic imaging and systemic radiotherapy has increased considerable because of the observation that GRP receptors (GRPr) are over-expressed in a variety of human tumor cells, such as prostate tumor cells. 177Lu-labeled peptides are attractive due to the excellent radiophysical properties and commercial availability of the radiometal. BEFG2 was successfully labeled with high yield and kept stable for more than 96 hours at 2-8º C and 1 hour in human plasma. Data analysis obtained from the in vivo studies showed that the amount of BEFG2 present in plasma decreased rapidly and became almost undetectable at 60 min p.i., indicating rapid peptide excretion, which is performed mainly by renal pathway. In addition, biodistribution and single photon emission tomography showed low abdominal accumulation of 177Lu-DOTA- Phe-X-BBN(6-14), indicating that this analog is a potential candidate for tumors target therapy.Artigo IPEN-doc 17127 Novel series of sup(177)Lu-labeled bombesin derivatives with amino acidic for selective targeting of human PC-3 prostate tumor cells2011 - PUJATTI, P.B.; SANTOS, J.S.; COUTO, R.M.; MELERO, L.T.U.H.; SUZUKI, M.F.; SOARES, C.R.J.; GRALLERT, S.R.M.; MENGATTI, J.; ARAUJO, E.B. de